Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai/UCL’s Anti-Tau Antibody Heading into PI for Alzheimer’s Disease
December 7, 2018
- U3-1402 Racks Up 42.9% Response Rate in Breast Cancer Study: Daiichi Sankyo
December 7, 2018
- Teva Takeda Yakuhin Applies for Pediatric Use for Blopress Based on Information in Public Domain
December 7, 2018
- Fuji Yakuhin, Pfizer to Terminate Copromotion for Topiloric in January
December 7, 2018
- Pfizer to Transfer Antiepileptic Agent Gabapen to Fuji Pharma
December 7, 2018
- Chugai Sues Alexion Japan over Soliris Successor ALXN1210 after US
December 6, 2018
- Amicus Aims to Expand Rare and Intractable Disease Pipeline in Japan
December 6, 2018
- Shareholders Give Blessing to £46 Billion Shire Pact as Weber Touts US Foothold
December 6, 2018
- Takeda Shareholders OK £46 Billion Shire Takeover
December 5, 2018
- Hemlibra Approved in Taiwan for Treatment of Hemophilia A with Inhibitors: Chugai
December 5, 2018
- Gilteritinib Shows High Response Rate in Previously Untreated AML Patients in PI: Astellas
December 5, 2018
- Elmed Eisai to Be Renamed “Elmed”, Move Headquarters to Toyama
December 5, 2018
- Takeda Family Member Comes Forward for Final Appeal to Veto Shire Deal, but Admits Uphill Battle
December 4, 2018
- Takeda Inks US$3.7 Billion Loan Accord with JBIC
December 4, 2018
- Ninlaro Shows 39% Improvement in PFS in Post-Transplant Multiple Myeloma Patients: Takeda
December 4, 2018
- Astellas Launches Sakigake-Designated AML Drug Xospata
December 4, 2018
- Fujifilm Toyama Chemical Licenses Cancer “Theragnostic” Agent to Novartis Subsidiary
December 4, 2018
- MSD Japan Chief Voices High Hopes for Keytruda Label Expansions
December 3, 2018
- With Current R&D Model Reaching Its Limit, Industry Going Digital to Boost Efficiency: Astellas Chairman
December 3, 2018
- Lilly Launches Breast Cancer Drug Verzenio
December 3, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…